EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Assessing the clinical meaningfulness of slowing CDR‐SB progression with disease‐modifying therapies for Alzheimer's disease

Sarah M Hartz iD, Suzanne E Schindler, Marissa L Streitz, Krista L Moulder, Jessica Mozersky, Guoqiao Wang, Chengjie Xiong, John C Morris

Alzheimer's & Dementia: Translational Research & Clinical Interventions · 2025-01 · 11 (1)

DOI: 10.1002/trc2.70033 ↗

At a glance

Journal article in Alzheimer's & Dementia: Translational Research & Clinical Interventions, published online on 2025-02-13. Written by Sarah M Hartz and 7 co-authors. Institution: Department of Psychiatry Washington University School of Medicine in St. Louis St. Louis Missouri USA. Cited 14 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIA NIH HHS, NIAAA NIH HHS, NCATS NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

INTRODUCTION For many patients and caregivers, a major goal of disease‐modifying treatments (DMTs) for Alzheimer's disease (AD) dementia is to extend independence in instrumental and basic activities of daily living (IADLs and BADLs). The goal of this study was to estimate the effect of treatments on the time remaining independent in IADLs and BADLs. METHODS Participants at the Knight Alzheimer Disease Research Center (Knight ADRC) who met eligibility criteria for recent DMT trials were studied: age ≥60 years at baseline, clinical diagnosis of very mild or mild AD dementia (global Clinical Dementia Rating [CDR] score 0.5 or 1), biomarker confirmation of amyloid pathology, and at least one follow‐up CDR assessment within 5 years. For IADLs, a subset of the Functional Assessment Questionnaire (FAQ) was examined that rated the degree of independence in the following: paying bills, driving, remembering medications and appointments, and preparing meals. For BADLs, the Personal Care domain of the CDR was used. Mixed‐effects logistic and ordinal regression models were used to examine the relationship between CDR Sum of Boxes (CDR‐SB) and the individual functional outcomes and their components. The change in CDR‐SB over time was estimated with linear mixed‐effects models. RESULTS A total of 282 participants were followed for an average of 2.9 years (standard deviation [SD] 1.3 years). For 50% of individuals, loss of independence in IADLs occurred at CDR‐SB >4.5 and in BADLs at CDR‐SB >11.5. For individuals with a baseline CDR‐SB = 2, treatment with lecanemab would extend independence in IADLs for 10 months (95% confidence interval [CI] 4–18 months) and treatment with donanemab in the low/medium tau group would extend independence in IADLs by 13 months (95% CI 6–24 months). DISCUSSION Independence in ADLs can be related to CDR‐SB and used to demonstrate the effect of AD treatments in extending the time of independent function, a meaningful outcome for patients and their families. Highlights We estimated time to loss of independence for people with AD dementia Estimating time to loss of independence can help with clinical decision‐making Disease‐modifying treatments for AD dementia can extend independence

Subjects

Author keywords

AD dementiaclinical meaningfulnessfunctional independence

Authors and institutions

  • Department of Psychiatry Washington University School of Medicine in St. Louis St. Louis Missouri USA.
  • Department of Neurology Washington University School of Medicine in St. Louis St. Louis Missouri USA.
  • Department of Medicine Washington University School of Medicine in St. Louis St. Louis Missouri USA.
  • Division of Biostatistics Washington University School of Medicine in St. Louis St. Louis Missouri USA.

ORCID profiles: Sarah M Hartz

Funding

  • NIA NIH HHS
  • NIAAA NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health

Cite

APA

Hartz, S. M., Schindler, S. E., Streitz, M. L., Moulder, K. L., Mozersky, J., Wang, G., Xiong, C., & Morris, J. C. (2025). Assessing the clinical meaningfulness of slowing CDR‐SB progression with disease‐modifying therapies for Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 11(1). https://doi.org/10.1002/trc2.70033

Vancouver

Hartz SM, Schindler SE, Streitz ML, Moulder KL, Mozersky J, Wang G, et al. Assessing the clinical meaningfulness of slowing CDR‐SB progression with disease‐modifying therapies for Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2025;11(1). doi:10.1002/trc2.70033

BibTeX
@article{Hartz2025,
  author = {Hartz, Sarah M and Schindler, Suzanne E and Streitz, Marissa L and Moulder, Krista L and Mozersky, Jessica and Wang, Guoqiao and Xiong, Chengjie and Morris, John C},
  title = {Assessing the clinical meaningfulness of slowing CDR‐SB progression with disease‐modifying therapies for Alzheimer's disease},
  journal = {Alzheimer's & Dementia: Translational Research & Clinical Interventions},
  year = {2025},
  volume = {11},
  number = {1},
  doi = {10.1002/trc2.70033}
}
Start for free →